Across the recent three months, 12 analysts have shared their insights on Aflac AFL, expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 0 | 7 | 2 | 0 |
| Last 30D | 0 | 0 | 0 | 1 | 0 |
| 1M Ago | 1 | 0 | 0 | 1 | 0 |
| 2M Ago | 1 | 0 | 4 | 0 | 0 |
| 3M Ago | 1 | 0 | 3 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Aflac, presenting an average target of $97.58, a high estimate of $115.00, and a low estimate of $83.00. Surpassing the previous average price target of $88.82, the current average has increased by 9.86%.
Interpreting Analyst Ratings: A Closer Look
The standing of Aflac among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Thomas Gallagher | Evercore ISI Group | Raises | Underperform | $90.00 | $84.00 |
| Alex Scott | Barclays | Announces | Underweight | $96.00 | - |
| Joshua Shanker | B of A Securities | Raises | Buy | $115.00 | $108.00 |
| Nigel Dally | Morgan Stanley | Raises | Equal-Weight | $98.00 | $91.00 |
| Brian Meredith | UBS | Raises | Neutral | $109.00 | $84.00 |
| Elyse Greenspan | Wells Fargo | Raises | Equal-Weight | $90.00 | $81.00 |
| Mark Hughes | Truist Securities | Raises | Hold | $100.00 | $82.00 |
| Joshua Shanker | B of A Securities | Raises | Buy | $108.00 | $105.00 |
| Michael Ward | Citigroup | Raises | Neutral | $93.00 | $84.00 |
| Joshua Shanker | B of A Securities | Raises | Buy | $105.00 | $95.00 |
| Suneet Kamath | Jefferies | Raises | Hold | $84.00 | $83.00 |
| Jimmy Bhullar | JP Morgan | Raises | Neutral | $83.00 | $80.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Aflac. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Aflac compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Aflac's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Aflac analyst ratings.
Discovering Aflac: A Closer Look
Aflac Inc offers supplemental health insurance and life insurance in United States and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accident, dental and vision, disability, and long-term-care insurance. It markets its products through independent distributors, selling majority of its policies directly to consumers at their places of work and also reaches out to its customers out of their worksite through digital mediums. The company has two reportable business segments; Aflac Japan which generates the majority of the revenue, and Aflac U.S.
Unraveling the Financial Story of Aflac
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Aflac's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -0.31%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Aflac's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 34.03% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Aflac's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 7.08%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Aflac's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.43% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.29.
The Basics of Analyst Ratings
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
